Kendall Capital Management Sells 175 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Kendall Capital Management reduced its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 2.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 7,869 shares of the specialty pharmaceutical company’s stock after selling 175 shares during the period. Kendall Capital Management’s holdings in Jazz Pharmaceuticals were worth $969,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. CIBC Asset Management Inc increased its stake in Jazz Pharmaceuticals by 5.2% in the 4th quarter. CIBC Asset Management Inc now owns 1,972 shares of the specialty pharmaceutical company’s stock valued at $243,000 after buying an additional 97 shares during the last quarter. UMB Bank n.a. increased its stake in Jazz Pharmaceuticals by 70.9% in the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock valued at $38,000 after buying an additional 129 shares during the last quarter. Jones Financial Companies Lllp increased its stake in Jazz Pharmaceuticals by 75.1% in the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock valued at $37,000 after buying an additional 130 shares during the last quarter. Waterfront Wealth Inc. increased its stake in Jazz Pharmaceuticals by 1.4% in the 4th quarter. Waterfront Wealth Inc. now owns 9,675 shares of the specialty pharmaceutical company’s stock valued at $1,191,000 after buying an additional 137 shares during the last quarter. Finally, Ellsworth Advisors LLC increased its stake in Jazz Pharmaceuticals by 0.4% in the 4th quarter. Ellsworth Advisors LLC now owns 37,962 shares of the specialty pharmaceutical company’s stock valued at $4,675,000 after buying an additional 149 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock opened at $138.81 on Friday. The company has a market cap of $8.43 billion, a price-to-earnings ratio of 19.55, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $148.06. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The firm has a 50 day moving average of $128.14 and a 200-day moving average of $120.03.

Insider Buying and Selling

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $122.31, for a total value of $183,465.00. Following the transaction, the chief executive officer now directly owns 439,744 shares in the company, valued at $53,785,088.64. This trade represents a 0.34 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CMO Robert Iannone sold 7,080 shares of the stock in a transaction on Friday, March 7th. The stock was sold at an average price of $138.60, for a total value of $981,288.00. Following the completion of the transaction, the chief marketing officer now owns 82,024 shares in the company, valued at approximately $11,368,526.40. This represents a 7.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 25,193 shares of company stock worth $3,533,122 in the last ninety days. Corporate insiders own 4.20% of the company’s stock.

Wall Street Analyst Weigh In

JAZZ has been the topic of several recent research reports. Morgan Stanley reiterated an “overweight” rating and issued a $183.00 price target (up from $175.00) on shares of Jazz Pharmaceuticals in a research note on Friday. Barclays restated an “overweight” rating and set a $200.00 price objective (up from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. Cantor Fitzgerald lowered shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and boosted their price objective for the stock from $140.00 to $150.00 in a research note on Wednesday, February 26th. Truist Financial boosted their price objective on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Royal Bank of Canada lowered their price objective on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $189.40.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.